Purpose: Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.0ng/ml e 10.0ng/ml). We introduce a new circulating-tumor-cell (CTC) biomarker for detection of prostate cancer in patients in the PSA "gray zone" level, with the clinically verified potential to substantially decrease the number of unnecessary prostate biopsies. Materials and Methods: A total of 97 patients underwent routine prostate screening including PSA testing and DRE. One tube of blood was drawn for each patient and sent for CTC analysis in a double blinded study. A subset of 23 patients with PSA in the 4.0ng/ml e 10.0ng/ml range was selected with consent to undergo prostate biopsy for comparison with blinded CTC test results. The CTC test utilized a microfluidic platform with EpCAM as capture antibody. Suspected CTCs were eluted to a membrane chip and immunofluorently stained with CK18, PSMA and CD45 antibody to confirm. Positive CTCs are defined as CK18+ or PSMA+ and CD45-. Results: Prostate cancer was confirmed by biopsy in 60 out of 97 patients. CTC assay reported 83% of the cancer cases, demonstrating prostate cancer detection ability of the assay. In the subset category of 23 patients (PSA in the 4.0ng/ml e 10.0ng/ml range, and prostate biopsy), the CTC assay was able to detect cancer in 100% of the prostate cancer cases. Conclusion: This CTC-based blood test is a valuable new tool in effective screening for prostate cancer. We have demonstrated that this new CTC biomarker is able to reduce unnecessary invasive prostate biopsies in the PSA "gray zone" by over 60%, with the potential to reduce cost to the system and reduce complication rates due to prostate biopsies, thus improving patient outcomes.
Tainan, Taiwan
Purpose: Urothelial carcinoma (UC) is the most common malignancy involving urinary bladder (UB) and upper urinary tract (UT) for which the theranostic markers remain under-investigated. Increasing evidence has shown that protein tyrosine phosphatases (PTPs) play dominant roles in setting the levels of tyrosine phosphorylation and promote oncogenic processes. However, their expression has not been systemically investigated in UC, and our aim is to examine their potential impact on UC. Materials and Methods: We performed data mining from a published transcriptome of UBUCs (GSE32894), and PTP type IVA member 3 (PTP4A3) was identified as the most significantly upregulated gene among those related to prenylated PTP activity (GO: 0004727). The importance of PTP4A3 was initially analyzed in paired normal urothelium, non-invasive UC, invasive UC, and nodal metastatic tissue. PTP4A3 transcript level was assessed in snap-frozen UC samples by laser capture microdissection and real-time RT-PCR. PTP4A3 protein expression was determined by immunohistochemistry in 295 UBUCs and 340 UTUCs, respectively. The association of PTP4A3 expression with clinicopathological features, disease-specific survival (DSS), and metastasis-free survival (MeFS) was further evaluated. Results: For both UBUC and UTUC, the level of PTP4A3 significantly increased from normal urothelium, non-invasive UC, invasive UC, to nodal metastatic tissue (both p < 0.001). The PTP4A3 transcript level was also markedly upregulated in high stage UC (UBUC, p < 0.001; UTUC, p ¼ 0.002). Overexpression of PTP4A3 protein was significantly associated with advanced pT status, nodal metastasis, and lymphovascular invasion (all p < 0.001). PTP4A3 overexpression not only predicted worse DSS and MeFS on univariate analysis (all p < 0.001), but also implicated in inferior DSS (UBUC, p < 0.001; UTUC, p ¼ 0. retrospectively as the derivation cohort to investigate the impact of inflammation markers on overall survival (OS) and cancer-specific survival (CSS). In turn, another independent set of 225 patients were used for validation. Finally, we performed survival analysis in the combined cohort consisting of 420 UTUC patients.
Results: The predictive value of RDW and WBC count on outcome was replicable in different cohorts. Multivariate analysis showed high RDW was independently associated with poor OS (P < 0.001), and WBC count was a significant prognosticator for both OS and CSS (both P < 0.001). In subgroup analysis, we found the prognostic significance of RDW for OS was limited in organ-confined disease ( pT2 without pN+). More importantly, a clear survival difference can be demonstrated by combining RDW and WBC count with other known prognostic factors in the risk stratification model. Conclusion: RDW and WBC count have the advantage of their common accessibility and are useful markers to predict outcome of UTUC in the preoperative setting. RDW and WBC count could provide additional prognostic value and help physicians identify patients at high risk for mortality and formulate individualized treatment strategy. Results: A total of 107 proteins out of 2964 proteins were identified in this approach as candidate biomarkers. Differences in the concentrations of 29 proteins were precisely quantified by LCÀMRM/MS. There were 24 proteins changed significantly (p < 0.05) between bladder cancer and hernia. TACSTD2 concentrations measured by LC-MRM/MS were 6.5-fold higher in bladder cancer urinary microparticles than in hernia urinary microparticles. In raw urine specimens (n ¼ 221) using ELISA, the area-under-thecurve values of TACSTD2 was 0.80. Conclusion: Our study revealed that TACSTD2 showed strong association with bladder canLcer in urine specimens, and thus represents a potential biomarker for noninvasive screening for bladder cancer. Results: The HK2 expression was significantly higher in bladder cancers compared with normal cells. The urine lactate detection was higher in human bladder cancers than in non-cancer subjects (204.9 vs 54.79 mM; P < 0.001). Stable HK2 overexpression induced cell proliferation, and showed morphologic changes with gain of cancer stem cell markers. HK2 knockdown also reduced lactate extrusion in vitro. In response to lactate exposure, nuclear translocation of NF-kB phosphorylation and Twist1 as well as mesenchymal markers was promoted in human bladder cancer cells. In addition, lactate exposure enhanced CD133 activity in vitro. In mice bearing subcutaneous tumors, increased tumor growth and lung metastasis were observed in stable HK2-overexpression cancers compared with mock counterparts (survival, P ¼ 0.034). In animal models, HK2-overexpression cancers also induced morphologic change and CD133 activity.
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